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Chronic spontaneous urticaria (CSU) is characterized by the recurrent 
appearance of wheals, angioedema or both, occurring at least twice weekly for longer 
than 6 weeks (1), often managed with antihistamines, but occasionally requiring other 
systemic agents in recalcitrant cases. 
A cross-sectional survey was conducted by means of an internet-based 
survey tool (Typeform). Participating consultants with a specialist interest in urticaria 
were identified and invited through the specialist registers of the British Society of 
Allergy and Clinical Immunology (BSACI), the Improving Quality in Allergy Services 
(IQAS) Group and the British Association of Dermatologists (BAD).  
The survey content was based on current CSU treatment guidelines from 
EAACI/GA2LEN/EDF/WAO  (2) and the British Society for Allergy and Clinical 
Immunology (BSACI) (3). The EAACI/GA2LEN/EDF/WAO guidelines are a joint 
initiative of the Dermatology Section of the European Academy of Allergy and 
Clinical Immunology (EAACI), the EU-funded network of excellence, the Global 
Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum 
(EDF), and the World Allergy Organization (WAO). . To standardise responses, all 
participants were presented with a case of recalcitrant CSU (failed on maximum dose 
non-sedating antihistamines and montelukast), requiring alternative systemic 
treatment. Questions covered usage of systemic treatments, routine disease severity 
assessments, adherence to treatment guidelines and perceived barriers to 
prescribing.  
Responses (table 1) were received from 19 UK consultants (completion rate 
73%), 15 of whom had greater than 10 years experience in the treatment of chronic 
spontaneous urticaria. The majority were allergy (58%) and dermatology consultants 
(37%) and 56% provide a dedicated urticaria service. 37% treat adult and paediatric 
patients, and the majority (79%) use other systemic medications than antihistamines 
and montelukast. Omalizumab and ciclosporin were the most commonly used first line 
agents (47% and 27% respectively) (figure 1). 84% use validated measures to assess 
disease severity, including the urticaria activity score (UAS-7, 63%), the Physician 
Global Assessment (63%), the Patient Global Assessment (44%) and the Dermatology 
Quality of Life Index (DLQI, 38%). 89% use guidelines to direct their management of 
chronic spontaneous urticaria, with 50% using the EAACI/GA2LEN/EDF/WAO guideline 
(2), compared to 31% primarily using the BSACI one (3). The main perceived barriers 
to prescribing systemic medications were potential adverse effects (32% strongly 
agreed), potential long term toxicity (26% strongly agreed), cost of treatment (42% 
strongly agreed), and views expressed by patients and their family (37% agreed). 
Our findings show variance between dermatology, allergy and immunology 
consultants with regard to the prescribing of systemic agents in CSU (figure 2). Our 
findings suggest allergists are more likely to prescribe omalizumab as first line 
treatment, while dermatologists more commonly prescribe ciclosporin, which is not 
in keeping with NICE guidance (5).  
Drug-related adverse effects are the main perceived barrier for clinicians to 
prescribe systemic medications. Other barriers to prescribing are the cost of 
medications. The list price for 300mg Omalizumab monthly for 12 months is £6150 
(4), excluding the cost of post-injection observations required in a secondary care 
setting, while  ciclosporin (in generic formulation) costs £2660 for 300 mg/day for 12 
months (4 mg/kg/day for 75 kg patient) (4), excluding the cost of renal function and 
blood pressure monitoring. The main limitation to our survey was the number of 
respondents, as we chose to focus on consultant physicians with a specialist interest 
in urticaria. 
In summary, our UK survey highlights the differences in management of CSU 
between dermatologists and other specialists, resulting in variation in the care 
provided for CSU patients. Although national and international treatment guidelines 
now recommend omalizumab as a first line agent for severe CSU not responding to 
antihistamine and montelukast treatment, these are based on placebo-controlled 
studies. The current lack of head-to-head comparisons between conventional 
systemics and biologic therapies may explain some of the variation in treatment 
approaches we observed and highlights the need for further research in this area, 
including a comprehensive health economic evalation. (5,6).  
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Table 1: Summary of survey results  
Section 1: Demographics  
Country of work United Kingdom 100% (19) 
Hospital grade Consultant 100% (19) 
Specialty Allergy 58% (11) 
Dermatology 37% (7) 
Immunology 5% (1) 
Caseload Adults only 42% (8) 
Both Adults and Paediatrics 37% (7) 
Paediatrics only 21% (4) 
Number of years in specialty >20 years 53% (10) 
10-20 years 26% (5) 
<10 years  21% (4) 
Section 2: Use of systemic medications 
Do you use systemic medication for the 
management of chronic urticaria? 
Yes 79% (15) 
No 21% (4) 
First line? Omalizumab 47% (7) 
Ciclosporin 28% (4) 
Other 20% (3) 
Dapsone 7% (1) 
Second line? Omalizumab 40% (6) 
Ciclosporin 33% (5) 
Mycophenolate Mofetil 13% (2) 
Other 13% (2) 
Third line? Other 27% (4) 
Dapsone 20% (3) 
Ciclosporin 13% (2) 
Methotrexate 13% (2) 
Mycophenolate Mofetil 13% (2) 
If you use any of the listed treatments in 
children, which ones do you use?  
Ciclosporin 80% (4) 
Omalizumab 80% (4) 
Azathioprine 60% (3) 
Dapsone 60% (3) 
Mycophenolate Mofetil 60% (3) 
Methotrexate 20% (1) 
Section 3: Use of standardised measures 
Do you use standardised measures when 
assessing disease? 
Yes 84% (16) 
No 16% (3) 
Physician global assessment Most of the time 63% (10) 
Sometimes 13% (2) 
Never 25% (4) 
Patient global assessment Most of the time 44% (7) 
Sometimes 25% (4) 
Rarely 6% (1) 
Never 25% (4) 
Urticaria activity score (UAS) 7 Most of the time 63% (10) 
Sometimes 38% (6) 
In-clinic UAS Most of the time 25% (4) 
Sometimes 13% (2) 
Rarely 19% (3) 
Never 44% (7) 
Angioedema activity score Sometimes 44% (7) 
Rarely 25% (4) 
Never 31% (5) 
Itch-severity score Most of the time 13% (2) 
Sometimes 19% (3) 
Rarely 31% (5) 
Never 38% (6) 
Weekly number of hives score Most of the time 13% (2) 
Sometimes 25% (4) 
Rarely 19% (3) 
Never 44% (7) 
DLQI Most of the time 38% (6) 
Sometimes 25% (4) 
Rarely 25% (4) 
Never 13% (2) 
Chronic Urticaria Quality of Life 
Questionnaire (CU-Q2oL) 
Sometimes 25% (4) 
Rarely 25% (4) 
Never 50% (8) 
Angioedema Quality of Life Questionnaire 
(AE-QoL) 
Sometimes 6% (1) 
Rarely 31% (5) 
Never 63% (10) 
Section 4: Use of guidelines and perceived barriers 
Do you use guidelines to direct your 
management of urticaria? 
Yes 89% (17) 
No 11% (2) 
Which guidelines do you refer to? EACCI/GA(2)LEN/EDF/WAO 50% (8) 
Other 38% (6) 
Local guidelines 13% (2) 
Support services for patients Access to nursing support 89% (16) 
Access to inpatient facilities 61% (11) 
Dedicated urticaria service 56% (10) 
Nurse prescribers 28% (5) 
Main perceived barriers to prescribing 
systemic medications 
Cost 
Side Effect of treatments 
Views expressed by patient or family 
Long term toxicity 
 Figure 1: First-, second- and third-line systemic drug selection  
 
Figure 2: First-, second- and third-line systemic drug selection by specialty 
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